Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
BNT329 enters the clinic, as do four other new ADCs.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.